Viral Resistance Increase Due To Denavir Switch Unlikely - SB Expert
This article was originally published in The Tan Sheet
Executive Summary
The proposed Rx-to-OTC switch of SmithKline Beecham's Denavir (penciclovir 1%) would "not cause any topical change in antiviral resistance," predicted Myron Levin, MD, University of Colorado Health Sciences Center, at a Dec. 1 joint review of the drug's switch potential by FDA's Nonprescription and Antiviral Drugs Advisory Committees.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning